Johnson & Johnson announced two-year Phase 3 results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor 1, showing sustained high skin clearance rates in adults and adolescents with moderate-to-severe plaque psoriasis. Nearly 72% of patients achieved 90% improvement in psoriasis severity, with over 70% having clear or almost clear skin at two years, alongside a consistent safety profile. These results highlight ICOTYDE as a promising long-term systemic therapy option, with ongoing studies exploring its use in related inflammatory diseases.
Johnson & Johnson shares trade at USD 255.71 on Pluang as of Oct 09, 2026 18:11 WIB, down 0.30% for the day. The stock holds a market cap of $618.09 billion, reflecting strong investor interest despite the slight dip. Most Pluang users are buying, with 96% of order activity favoring purchases, showing confidence in the company amid its new long-term data announcement.
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
Four Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo—continue to deliver steady dividends, crucial for retirees relying on portfolio income. Johnson & Johnson and Procter & Gamble show very safe dividend payouts with health...
Five major U.S. companies—Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo, and Realty Income—are highlighted for their long histories of dividend increases and strong cash flow coverage. These firms offer diverse dividend yields, with some pr...
Pfizer offers a dividend yield of 6.24%, much higher than Johnson & Johnson's 2.07%, but Pfizer's payout is frozen and not fully covered by free cash flow, with rising debt and a recent $4.3 billion write-down signaling risk. Johnson & Johnson, despi...
Johnson & Johnson has achieved its 64th consecutive year of dividend increases, raising its quarterly dividend by 3.1% to $1.34 per share in 2026. Despite strong overall sales growth driven by new drugs like Tremfya and Darzalex, the company faces si...
